Exposure of female August-Copenhagen Irish (ACI) rats for 28 weeks to 3 mg of estradiol (E 2 ) contained in cholesterol pellets elevated blood E 2 levels and caused palpable mammary tumors in all animals. Coadministration of phenobarbital (PB) in their drinking water reduced the incidence, number, and size of mammary tumors (MTs) but did not reduce blood E 2 levels. Inhibition of MTs by PB was accompanied by significant changes in total hepatic metabolism of E 2 measured in vitro. PB treatment caused approximately a 4-fold increase in hepatic metabolism of E 2 in control and E 2 -treated rats. The major NAD(P)H-dependent metabolites of E 2 were 2-OH-E 2 and estrone (E 1 ). PB, either alone or together with E 2 , increased microsomal 2-hydroxylation of E 2 ; formation of E 1 was either unaffected or decreased slightly. PB also increased microsomal metabolism of E 2 to minor metabolites (4-OH-E 2 , 6␣-OH-E 2 , 6␤-OH-E 2 , 14␣-OH-E 2 , 6-keto E 1 , and 2-OH-E 1 ) and reduced the formation of the E 2 -17␤-oleoyl ester and the E 2 3-and 17-glucuronides. In contrast, when given in combination with E 2 , PB increased the formation of both glucuronides. Cotreatment of animals with PB and E 2 increased activities of NAD(P)H:quinone oxidoreductase and glutathione S-transferase to a greater extent than either compound alone. Collectively, these results show that the multiple actions of PB on hepatic metabolism of E 2 , including induction of E 2 hydroxylation, glucuronidation, and antioxidant defense enzymes along with inhibition of E 2 esterification in livers of female ACI rats, accompany a marked reduction of E 2 -dependent mammary tumors in this model. (Conney et al., 1973) . Treatment of rodents with PB induces the synthesis of hepatic microsomal enzymes that hydroxylate progesterone, estradiol (E 2 ), estrone (E 1 ), deoxycorticosterone, testosterone, ⌬ 4 -androstene-3,17-dione, and cortisol (reviewed by Zhu and Conney, 1998) . Endogenous estrogens are hydroxylated at multiple positions by several hepatic and nonhepatic microsomal monooxygenase systems (reviewed by Martucci and Fishman, 1993; Zhu and Conney, 1998) . The alteration of microsomal hydroxylation of steroids by PB is reflected in vivo by enhanced metabolism and altered actions of steroids. For example, pretreatment of rats with PB decreases the uterotropic action of E 2 and E 1 and enhances their metabolism in vivo (Levin et al., 1967 (Levin et al., , 1968 . Treatment of rats with PB also inhibits the growth-promoting effect of testosterone on the seminal vesicles (Levin et al., 1974) and decreases the anesthetic action of progesterone and deoxycorticosterone in rodents (Conney et al., 1966) .
mal metabolism of E 2 to minor metabolites (4-OH-E 2 , 6␣-OH-E 2 , 6␤-OH-E 2 , 14␣-OH-E 2 , 6-keto E 1 , and 2-OH-E 1 ) and reduced the formation of the E 2 -17␤-oleoyl ester and the E 2 3-and 17-glucuronides. In contrast, when given in combination with E 2 , PB increased the formation of both glucuronides. Cotreatment of animals with PB and E 2 increased activities of NAD(P)H:quinone oxidoreductase and glutathione S-transferase to a greater extent than either compound alone. Collectively, these results show that the multiple actions of PB on hepatic metabolism of E 2 , including induction of E 2 hydroxylation, glucuronidation, and antioxidant defense enzymes along with inhibition of E 2 esterification in livers of female ACI rats, accompany a marked reduction of E 2 -dependent mammary tumors in this model. Phenobarbital (PB) is a known inducer of microsomal hydroxylation of drugs and steroids in rodents and in humans (Conney et al., 1973) . Treatment of rodents with PB induces the synthesis of hepatic microsomal enzymes that hydroxylate progesterone, estradiol (E 2 ), estrone (E 1 ), deoxycorticosterone, testosterone, ⌬ 4 -androstene-3,17-dione, and cortisol (reviewed by Zhu and Conney, 1998) . Endogenous estrogens are hydroxylated at multiple positions by several hepatic and nonhepatic microsomal monooxygenase systems (reviewed by Martucci and Fishman, 1993; Zhu and Conney, 1998) . The alteration of microsomal hydroxylation of steroids by PB is reflected in vivo by enhanced metabolism and altered actions of steroids. For example, pretreatment of rats with PB decreases the uterotropic action of E 2 and E 1 and enhances their metabolism in vivo (Levin et al., 1967 (Levin et al., , 1968 . Treatment of rats with PB also inhibits the growth-promoting effect of testosterone on the seminal vesicles (Levin et al., 1974) and decreases the anesthetic action of progesterone and deoxycorticosterone in rodents (Conney et al., 1966) .
Oxidative stress arising from redox cycling of catechol estrogens formed during E 2 metabolism has been suggested as an important factor in initiation and progression of many cancers, including mammary carcinogenesis (Cavalieri et al., 1997; Cavalieri and Rogers, 2004) . In mammals, the liver contains high levels of cytochromes P450, which catalyze NAD(P)H-dependent oxidation of estrogens to various hydroxylated or keto metabolites (Martucci and Fishman, 1993; Zhu and Conney, 1998) . Reaction of endogenous catechol estrogens with DNA causes formation of depurinating DNA adducts (Cavalieri et al., 1997; Cavalieri and Rogers, 2004; Li et al., 2004) , which has been proposed to cause oncogenic mutations (Chakravarti et al., 1995) . The carcinogenic effects of 4-catechol estrogens (E 2 and E 1 ) in the kidney of castrated male Syrian hamsters (Liehr et al., 1986 ) reinforce this hypothesis. However, administration of high doses of 2-OH-E 2 , 4-OH-E 2 , or 4-OH-E 1 to ACI rats failed to cause mammary tumors under conditions in which E 2 was highly active (Turan et al., 2004) . In addition, the direct injection of estrone-3,4-quinone (the chemically reactive ortho-quinone derived from 4-OH-E 1 ) under the nipples of the mammary glands in rats failed to cause mammary tumors, whereas injection of a positive control, a diol epoxide of benzo[c]phenanthrene, was highly active (el-Bayoumy et al., 1996) .
In the present study, we investigated the effects of PB on the formation of mammary tumors induced by E 2 in ACI rats, an estrogen-sensitive strain that is considered a unique model because of its high sensitivity to estrogen-dependent mammary ductal adenocarcinomas (80 -100% incidence) within a relatively short time period (Shull et al., 1997; Harvell et al., 2000; Li et al., 2002) . The main objective of the present study was to determine whether PB-induced increases in E 2 metabolism in the liver corresponded with alterations in the formation of E 2 -induced mammary tumors. The liver is a major site of estrogen metabolism, and estrogen circulates primarily as inactive conjugates of E 1 and E 2 produced in the liver; i.e., conjugated E 2 is a transport form of estrogen, which is converted back to active estrogen in target tissues such as mammary gland (reviewed in Zhu and Conney, 1998; Pasqualini 2004; Reed et al., 2005) 
Materials and Methods

Chemicals
E 2 , ascorbic acid, NAD(P)H, ␤-glucuronidase (EC 3.2.1.31), UDPglucuronic acid (UDPGA), sodium phenobarbital, saccharic acid 1,4-lactone, p-nitrophenol, 1-chloro-2,4-dinitrobenzene (CDNB), reduced glutathione, cytochrome c, oleoyl coenzyme A, sodium azide, and Tris base were obtained from Sigma Chemical (St. Louis, MO). Glutathione reductase (140.7 U/mg protein) was purchased from Fluka Biochemica (Buchs, Switzerland), [
35 S]PAPS was purchased from New England Nuclear (Boston, MA), and PAPS (Ͼ99% pure) was purchased from H. Glatt and R. Landseidel, German Institute of Nutrition (Potsdam, Germany) . [2,4,6,7,16,17- 3 H]Estradiol (s.a. 110 -170 Ci/mmol) was purchased from NEN Life Science Products (Boston, MA). Pellets with or without E 2 were purchased from Hormone Pellets Press (Shawnee Mission, KS). AIN-76A diet was purchased from Dyets Inc. (Bethlehem, PA). All other chemicals used were of the highest grade from standard sources.
Animals and Treatments
Female ACI rats (7-8 weeks old) were obtained from Harlan Sprague-Dawley Laboratory (Indianapolis, IN). The animals were housed individually in an Association for Assessment and Accreditation of Laboratory Animal Care International-accredited barrier facility under controlled temperature, humidity, and lighting conditions and were fed with AIN-76A diet (Dyets Inc.). Treatment protocols started 4 days after arrival of the animals. Rats received water ad libitum or 0.05% PB in their drinking water. A single 20-mg pellet containing 3 mg of E 2 plus 17 mg of cholesterol was implanted subpannicularly in the shoulder region, as described previously . Control animals were implanted with 20-mg cholesterol pellets alone. The rats were palpated for mammary tumors twice weekly and were weighed every 2 weeks for the duration of the experiment. Animals (n ϭ 8 -15) were killed by decapitation after 6, 12, or 28 weeks. The geometric volume of the tumors was determined using the formula: length ϫ width ϫ height ϫ 0.5326, assuming a hemiellipsoid shape (Shah et al., 1999) .
Serum Levels of E 2 . Trunk blood collected at decapitation was allowed to clot at 4°C for 6 h and centrifuged. The serum was collected and stored at Ϫ80°C. Circulating levels of E 2 were determined in whole serum by radioimmunoassay, using Coat-A Count Estradiol RIA kits (Diagnostic Products, Los Angeles, CA). According to the manufacturer's instructions, this assay measures both bound and free E 2 in serum.
Tissue Processing. All of the animals were subjected to macroscopic pathologic examination when killed, and the number, volume, and localization of mammary tumors were recorded. The mammary glands and the tumors were quickly removed. Portions of these tissues were fixed in Carnoy's solution for 4 h and processed for embedding in paraffin. Sections (6 m) were prepared from each of the Carnoy's solution-fixed tissues and stained with hematoxylin and eosin. Selected estrogen target organs, including pituitary, adrenals, thymus, uterus, kidneys, and liver, were removed and weighed.
Preparation of Hepatic Subcellular Fractions. Liver cytosols and microsomes were prepared by differential centrifugation as described previously (Thomas et al., 1983 ) and stored at Ϫ80°C until used. The protein concentration was determined with the BCA protein assay kit (Pierce Chemical, Rockford, IL) according to the supplier's instructions using bovine serum albumin as a standard.
Enzyme Assays
NAD(P)H-dependent oxidation of E 2 (cytochrome P450 assay) was carried out using liver microsomes incubated with 5 mM ascorbic acid, 3 mM magnesium chloride, 50 M sodium phosphate buffer (pH 7.4), and 25 M [ 3 H]E 2 (0.5 Ci) for 20 min at 37°C. The enzyme reaction was initiated with 2 mM NAD(P)H and terminated by the addition of 5 ml of ethyl acetate and vortexing. The ethyl acetate extracts were evaporated to dryness under nitrogen. The residue was dissolved in methanol and analyzed for metabolite composition by HPLC as described previously (Suchar et al., 1996; Mesia-Vela et al., 2002) .
Fatty acyl-CoA:estradiol acyltransferase was assayed in reaction mixtures containing 50 M [ 3 H]E 2 (1 Ci), 100 M fatty acyl-CoA, and 5 mM magnesium chloride in 0.1 M sodium acetate buffer (pH 5.5) in a final volume of 0.5 ml. The reaction was initiated by the addition of liver microsomes (1 mg of protein/ml). After incubation at 37°C for 30 min, the reaction was arrested by placing the tubes on ice, followed by the addition of 0.2 ml of ice-cold sodium acetate buffer (pH 5.5) and extraction by vortexing with 4 ml of ethyl acetate (HPLC grade from Fisher Scientific, Pittsburgh, PA). Dry extracts were redissolved, and 90-l aliquots were analyzed by HPLC as described previously (Xu et al., 2002) . Metabolite quantification was based on the amount of radioactivity in the metabolite peak compared with the total radioactivity collected from the HPLC column from each sample.
Glucuronosyltransferase activity was assayed using a modification of a previously described method (Sanchez et al., 2003) . The reaction mixture contained 1.0 mg of microsomal protein, 2 mM UDPGA, 5 mM MgC1 2 , 100 M [ 3 H]E 2 (0.15 Ci), and 50 mM Tris-HCl buffer, pH 8.5, in a final volume of 150 l. The reaction was initiated by the addition of UDPGA. Incubations proceeded at 37°C for 15 min and were terminated by placing them on ice and adding 50 l of ice-cold acetonitrile. The reaction mixtures were then vortexed and centrifuged at 3000g for 5 min, and 10 l of the supernatants were used for the determination of E 2 and E 2 glucuronides by HPLC. The HPLC system consisted of a Shimadzu SCL-10A system controller with a Shimadzu SIL-10A autoinjector, two LC-10AD pumps, a SPD-10A UV-visible detector set at 280 nm, and an Eclipse XDB C 18 (4.6 ϫ 150 mm) column (MacMod Analytical, Chadds Ford, PA). The solvent system consisted of solvent A (0.1% acetic acid in water) and solvent B containing 20% methanol, 80% acetonitrile, and 0.1% ace-
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at ASPET Journals on June 9, 2017 jpet.aspetjournals.org tic acid. E 2 and its 3-and 17-hydroxyglucuronides were eluted with a 30-min linear gradient from 25 to 90% solvent B. Metabolite quantification was based on the amount of radioactivity in the metabolite peak compared with the total radioactivity collected from the HPLC column from each sample. The retention time of metabolites and E 2 agreed with corresponding UV-absorbing peaks of standards. The glucuronides were identified by their coelution with authentic standards or by determination of E 2 after hydrolysis in the presence of ␤-glucuronidase (200 U/ml).
Cytosolic sulfotransferase (SULT) activity was determined using [ 35 S]PAPS as cofactor. The incubations were carried out with 20 mM Tris⅐HCl, pH 7.5, 4 mM MgCl 2 , 10 M [
35 S]PAPS (0.02 Ci), and 5 M p-nitrophenol in 100 l (Foldes and Meek, 1973) . Cytosolic NAD(P)H/quinone oxidoreductase (NQO1) was measured by reduction of cytochrome c (50 M) in the presence of liver cytosol, 10 M menadione, and 1 mM NAD(P)H. The reaction was monitored at 550 nm. The reactions were carried out in 100 mM potassium phosphate buffer, pH 7.7, containing 0.04% Triton X-100 at 25°C (Jaiswal et al., 1988) . Activity of dicumarol-inhibitable menadione reductase was determined using an extinction coefficient of 21 mM/cm for cytochrome c.
Cytosolic glutathione S-transferase (GST) activity was measured in the presence of liver cytosolic protein, 1 mM CDNB, 1 mM reduced glutathione, and 100 mM potassium phosphate buffer, pH 6.5, at 25°C. Conjugation of CDNB with glutathione was monitored at 340 nm. Specific activity was calculated using an extinction coefficient of 9.6 mmol/cm (Habig et al., 1974) .
Cytosolic glutathione peroxidase (GPx) activity was measured using hydrogen peroxide as the substrate and was monitored by the decrease in absorbance at 340 nm. Specific activity was calculated using an extinction coefficient for NAD(P)H of 6.22 mM/cm (Flohe and Gunzler, 1984) .
Statistical Analysis of Data
Data are presented as the means Ϯ S.E. Differences between means were assessed by ANOVA followed by the Bonferroni post hoc test, P Ͻ 0.05.
Results
Tissue Wet Weights and Histopathology in PB-and E 2 -Treated ACI Rats
Administration of E 2 increased pituitary weight by 3.5-and 4.8-fold after 6 and 12 weeks of treatment, respectively. These E 2 -dependent increases in pituitary weights were not reduced by coadministration of PB (Table 1) . A small increase in kidney weight (36%) and a reduction of thymus weight were also observed in the group treated with E 2 for 6 to 12 weeks (Table 1) . Relative liver weight was increased approximately 1.5-fold by E 2 at both experimental periods (Table 2) . Administration of PB also enhanced the E 2 -induced increase in the relative liver weight, indicating differential effects on liver by both drugs. A 2-to 2.6-fold increase in the microsomal protein per liver after 6 and 12 weeks of PB treatment reflected the induction of microsomal protein by PB treatment (Table 2) . PB alone or in combination with E 2 slightly increased adrenal weights at 6 weeks (Table 1) . No alteration of body or uterine weight was seen during PB or E 2 treatment. It is noteworthy that PB did not alter E 2 -dependent increases in pituitary weights (Table 1 ). Significant losses in body weight were noted at approximately 20 weeks when large palpable mammary tumors were seen in E 2 -treated rats. In addition, pathology studies showed key changes in liver and mammary tissue. In liver, there was an increase of mitotic figures and scattered single cell degeneration caused by E 2 treatment alone. These effects diminished with time of exposure. Administration of PB alone induced enlargement of hepatocytes and vacuolar degeneration that increased markedly with the time of exposure to the drug. In contrast, for coadministered PB and E 2 , the effects of PB were predominant with a reduction of the scattered single cell degeneration induced by E 2 . In mammary samples, pronounced hyperplasia of mammary ductal cells due to E 2 treatment was observed. No quantitative difference could be observed in the extent of hyperplasia induced by E 2 in relation to time of exposure, but some of the samples from the 12-week exposure group showed major ductal changes and atypia. PB treatment alone did not alter the morphology of mammary tissue. Mammary tumors classified as mammary ductal adenocarcinomas were histologically similar in animals treated with E 2 alone or E 2 plus PB.
Effect of PB on the Incidence, Multiplicity, and Size of Mammary Tumors in E 2 -Treated ACI Rats
The first mammary tumor appeared during the 15th week in E 2 -treated rats. Fifty percent of the animals had mammary tumors by the 26th week, and 100% of the animals had TABLE 1 Time course effects on organ weights of female ACI rats receiving phenobarbital alone or in combination with estradiol E 2 (3 mg) was delivered in a 20-mg cholesterol pellet; 0.05% sodium phenobarbital was given in the drinking water. Control animals received water and a 20-mg cholesterol pellet only. Data are presented as means Ϯ S.E. of eight to 11 animals per group. (Fig. 1) . Treatment of the rats with PB had a dramatic inhibitory effect on the number and size of E 2 -induced mammary tumors observed at 28 weeks (96 -97% inhibition) (Fig. 2) .
Serum E 2 Levels
Treatment of female ACI rats with E 2 increased normal serum E 2 levels by 9-and 6-fold after 6 and 12 weeks of treatment, respectively. PB alone did not alter the serum level of total E 2 in normal or E 2 -treated rats at any of the periods of the study (Fig. 3) .
Effect of PB Administration on the NAD(P)H-Dependent Oxidative Metabolism of E 2 by Liver Microsomes
2-OH-E 2 and E 1 were the major metabolites formed during the incubation of E 2 with control liver microsomes and NAD(P)H (Table 3) . Treatment of the rats with PB for 6 and 12 weeks increased the formation of 2-hydroxy-E 2 per liver by 4.7-and 6.6-fold, respectively, compared with E 2 -treated rats. Treatment of the rats with PB for 6 and 12 weeks prevented the increase in formation of E 1 induced by chronic E 2 treatment. In addition to the above results, PB administration also caused substantial increases in the metabolism of E 2 to 6␣-hydroxy-E 2 , 6␤-hydroxy-E 2 , 14␣-hydroxy-E 2 , 4-hydroxy-E 2 , 6-keto-E 2 , and 2-hydroxy-E 1 per liver (calculated from Tables 2 and 3 ). Because the latter compounds are relatively minor metabolites, the overall major effect of PB was to enhance the 2-hydroxylation of E 2 as well as the 2-hydroxylation of E 1 .
Effect of PB Administration on the Esterification of E 2 by Fatty Acyl-CoA:E 2 -Acyltransferase in Liver Microsomes
Treatment of rats with E 2 for 6 or 12 weeks had little or no effect on liver microsomal formation of E 2 -17␤-oleoyl ester compared with control rats (calculated from Tables 2 and 4); however, coadministration of PB and E 2 reduced the esterification of E 2 by fatty acyl-CoA:E 2 -acyltransferase significantly at both 6 and 12 weeks (Table 4) . PB treatment alone decreased esterification of E 2 only after 12 weeks of treatment. Fig. 1 . Inhibition of mammary adenocarcinomas by phenobarbital in the ACI rat. E 2 was delivered in cholesterol pellet implants. Animals (8 -11 per group) were examined twice a week for tumors and were killed when the tumors reached 3 cm 2 or at the end of the experiment (28 weeks). PB treatment reduced the incidence of mammary tumors by 47%. Fig. 2 . Reduction of multiplicity and growth of E 2 -induced mammary adenocarcinomas by phenobarbital in the ACI rat. Phenobarbital reduced the multiplicity (tumors/rat) (A) and growth (tumor size/rat) (B) of E 2 -induced mammary tumors by Ͼ95%. The data presented are average values Ϯ S.E. from 8 to 11 animals per group killed at 28 weeks of treatment. ‫,ء‬ Statistically significant (P Ͻ 0.05) compared with E 2 -treated group (unpaired Student's t test).
Inhibition of Adenocarcinomas by Phenobarbital in ACI Rats
593
at ASPET Journals on June 9, 2017 jpet.aspetjournals.org
Downloaded from
Effect of PB Administration on the Glucuronidation of E 2 by Liver Microsomes
Treatment of rats with E 2 for 6 or 12 weeks did not alter microsomal glucuronidation of E 2 per milligram of Microsol protein at any experimental time; however, treatment with PB reduced the formation of both E 2 glucuronides (3-and 17-) by 45 and 34%, respectively, at 12 weeks. When given in combination with E 2 , PB increased formation of both glucuronides by 1.2-to 1.5-fold/mg protein after 6 and 12 weeks, respectively (calculated from Tables 2 and 4).
Effect of E 2 and PB Administration on Sulfotransferase and Antioxidant Enzymes in the Liver
Hepatic Sulfotransferase. E 2 administration for 6 or 12 weeks decreased p-nitrophenol sulfonation per milligram of cytosolic protein by ϳ30% (Table 5 ). Administration of PB had little or no effect on p-nitrophenol sulfonation (SULT1A1) activity when given alone or together with E 2 (Table 5) .
Antioxidant Enzymes. Although administration of PB caused a modest decrease in hepatic GPx activity per milligram of cytosolic protein and E 2 treatment was inactive, the administration of E 2 or PB for 6 or 12 weeks caused large increases in hepatic NQO1 and GST activity (Table 6 ). Administration of PB for 6 or 12 weeks caused a 3.7-to 4.2-fold increase in NQO1 activity per milligram of cytosolic protein, and administration of E 2 alone increased this activity 2.6-to 3.7-fold (Table 6 ). Administration of PB for 6 and 12 weeks elevated GST activity 2.7-to 2.9-fold per milligram of cytosolic protein; and administration of E 2 alone increased this activity 1.9-to 2-fold (Table 6 ).
The administration of a combination of PB and E 2 in- Percentage of E 2 metabolized.
* Statistically different from the water control group. ** Statistically different from the E 2 -treated group (ANOVA followed by the Bonferroni post hoc test) (P Ͻ 0.05). Fig. 3 . Serum E 2 levels after chronic treatment of ACI rats with E 2 . Data are presented as means Ϯ S.E. of 8 to 11 animals per group. ‫,ء‬ Statistically significant (P Ͻ 0.001) compared with groups not treated with E 2 (unpaired Student's t test).
creased NQO1 activity 68 to 84% (4.9-to 6.3-fold) compared with the activity observed after administration of E 2 alone. Administration of a combination of PB and E 2 also increased GST activity beyond that seen with either compound alone (3.1-to 3.9-fold per mg of cytosolic protein) (Table 6 ). In summary, administration of E 2 or PB alone caused large increases in the levels of the antioxidant enzymes, NQO1, and GST per milligram of cytosolic protein, and the effects of the combined administration of PB and E 2 were even larger than those after administration of E 2 or PB alone.
Discussion
The frequency, size, and number of mammary tumors induced in female ACI rats chronically treated with E 2 were reduced dramatically by PB given in the drinking water (Figs. 1 and 2) . The reduction of E 2 -dependent mammary tumors noted in animals exposed to PB indicates that very potent mechanisms of protection are activated by this compound in ACI rats. Surprisingly, the dramatic decrease in mammary tumors in PB-treated rats did not correlate with levels of serum E 2 measured in animals given E 2 chronically (Fig. 3) . The failure of pituitary and uterine weights, which normally change in response to the "estrogenicity" of serum in vivo, to change in rats cotreated with E 2 and PB is in accord with the finding that total E 2 levels were essentially the same in serum from both groups of animals. Further studies to characterize bound and free forms of E 2 and its metabolites in serum and mammary tissue of rats treated with E 2 alone or in combination with PB over the course of mammary tumor generation are needed in future studies using the ACI rat model.
The inhibition of E 2 -dependent tumorigenesis by PB was accompanied by significant changes in both the oxidation of E 2 and by smaller changes in conjugation reactions. In addition, PB treatment had a remarkable stimulatory effect on two antioxidant defense enzymes, NQO1 and GST, which may be particularly important for the protection of PB against mammary tumorigenesis in the ACI rat model. Because blood E 2 levels were unchanged after PB, it is possible that E 2 synthesis was enhanced to compensate for increased E 2 metabolism. Further studies to clarify the relationship between alterations in hepatic metabolism of E 2 and the profile of E 2 metabolites in blood over the course of mammary tumor formation in the ACI rat model are clearly warranted.
Chemoprevention of E 2 -Induced Mammary Tumors and Modulation of Microsomal Oxidation of E 2 by PB.
The chemopreventive effect of PB probably involves multiple mechanisms including an increase in microsomal oxidation triggered by PB. The strong stimulatory effect of PB on the hepatic formation of E 2 -hydroxylated E 2 metabolites including some that are formed only in trace amounts, if at all, in control animals (4-hydroxy-E 2 , 6␣-hydroxy-E 2 , 14␣-hydroxy-E 2 , 6␤-hydroxy-E 2 , and 6-keto-E 1 ) is noteworthy. The formation and pattern of induction of hydroxylated metabolites of E 2 by PB were similar to findings in other rat strains (Suchar et al., 1996) , which differ from the ACI rat in sensitivity to E 2 -induced mammary tumors. The major hydroxylated metabolite produced in the liver of the ACI rat is 2-hydroxy-E 2 . This metabolite, which is potentially chemopreventive against mammary tumors, was markedly induced in liver microsomes by PB in rats also treated with E 2 . A number of studies indicated that the 2-methoxy derivative of this metabolite formed by catechol O-methyl transferase has strong antiproliferative and proapoptotic actions in a variety of human cancer cell lines, including human breast cancer lines in vitro (Lottering et al., 1992; Pribluda et al., 2000; Liu and Zhu, 2004) . Furthermore, 2-methoxy-E 2 has strong antiangiogenic and inhibitory effects on growth of mammary tumors in mice in vivo (Fotsis et al., 1994; Klauber et al., 1997) . Recently, synergistic inhibitory effects of 2-methoxy-E 2 and microtubule-disrupting agents were observed on the proliferation of human breast cancer cells (Han et al., 2005) . Thus, the marked stimulatory effect of PB on the 2-hydroxylation of E 2 may contribute to the inhibitory effect of PB on E 2 -induced mammary tumors in the ACI rat. The other hydroxylated metabolites, some of which (e.g., 4-hydroxy-E 2 ) may be tumorigenic (Liehr 1997) , were also increased to a variable extent by PB. Transport of some of these metabolites either 
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at ASPET Journals on June 9, 2017 jpet.aspetjournals.org in their free or conjugated form to mammary tissue may contribute to mammary tumorigenesis either by direct genomic effects or via oxidative stress in mammary tissue. It is unlikely that circulating 4-hydroxy-E 2 , 4-hydroxy-E 1 , or 16␣-hydroxy-E 2 contributes to the carcinogenic effects of E 2 in the ACI rat because these metabolites of E 2 were not tumorigenic under conditions described above in which E 2 caused mammary tumors (Turan et al., 2004) . In addition, the direct injection of estrone-3,4-quinone (the chemically reactive ortho-quinone derived from 4-OH-E 2 ) under the nipples of the mammary gland in CD rats failed to cause mammary tumors (el-Bayoumy et al., 1996) . It is of interest that injection of 4-hydroxy-E 2 or E 2 -3,4-quinone into the mammary gland of the female ACI rat resulted in 4-hydroxy-E 2 -1-N 3 -adenosine and 4-hydroxy-E 2 -1-N 7 -guanine adducts in DNA ). It will be of interest to determine whether these injections result in mammary cancer.
Chemoprevention of E 2 -Induced Mammary Tumors and Modulation of E 2 Conjugation by PB. E 2 3-and 17-glucuronidation, major inactivation pathways of E 2 , were modestly increased when PB was coadministered with E 2 . In contrast, glucuronidation of E 2 was reduced by PB treatment alone at 12 weeks. Reduction in the capacity of liver to form E 2 glucuronides after chronic exposure to PB may increase amounts of active E 2 available for transport to E 2 target tissues such as mammary tissue. However, when PB was given concomitantly with E 2 , the formation of E 2 3-and 17-glucuronide was modestly increased, suggesting enhanced inactivation of E 2 in these animals. Reduction of microsomal fatty acyl-CoA:E 2 acyltransferase activity in PBtreated rats would reduce the formation of fatty acyl esters of E 2 , which are postulated to be long-term storage forms of E 2 in fatty tissues such as the breast (Xu et al., 2002) . Furthermore, hepatic cytosolic sulfotransferase (SULT1A1), which may be involved in the conversion of E 2 to conjugates that serve as transport and storage forms, was also decreased slightly by treatment with combinations of PB and E 2 .
Chemoprevention of E 2 -Induced Mammary Tumors and Modulation of Antioxidant Pathways by PB and E 2 . The observation that administration of PB alone or together with E 2 strongly induced the activity of NQO1 and GST in liver after 6 and 12 weeks of treatment is intriguing because these activities may be linked to detoxification of reactive oxygen species generated by redox cycling of E 2 catechols, and increased levels of these antioxidant enzymes have been associated with anticarcinogenic effects (RamosGomez et al., 2001) . It is very important to determine whether the actions of PB observed in liver also occur in mammary tissue. The effects of PB on NQO1 and GST in liver were opposite to those on GPx and were in accord with the idea that regulation of expression of GPx differs from that of NQO1 and GST (Radjendirane et al., 1998; Esposito et al., 2000) . It is also of considerable interest that administration of E 2 alone increases the level of antioxidant enzymes, a finding observed earlier by our group (Sanchez et al., 2003; Mesia-Vela et al., 2004) . Moreover, the induction of NQO1 and GST in response to chronic treatment with E 2 seems to be specific for the ACI rat (Sanchez et al., 2003) . The stimulatory effect of PB administration alone or together with E 2 on NQO1 and GST activity suggests that PB induction of antioxidant enzymes may play a role in the protective effect of PB on E 2 -induced breast cancer.
In conclusion, the growth and multiplicity of E 2 -dependent mammary tumors in the ACI rat is markedly reduced by PB in the drinking water. This reduction of mammary tumors in the ACI rat is accompanied by multiple effects of PB on hepatic metabolism, including induction of E 2 hydroxylation via NAD(P)H-dependent oxidations (predominantly an increase in 2-hydroxy-E 2 formation), by an alteration in the formation of E 2 conjugates, and by the induction of important antioxidant defense activities. Such changes induced by PB may reduce the incidence of mammary tumors by 1) enhancing the formation of a metabolite (2-methoxy-E 2 ) that is inhibitory to mammary tumor growth, 2) decreasing the formation of fatty acid esters of E 2 metabolites that serve as long-term depot forms of hormone in mammary tissue, 3) maintaining the formation E 2 glucuronidation in animals treated chronically with the hormone, and 4) elevation of antioxidant defense enzymes. Thus, PB-induced alterations in hepatic E 2 metabolism leading to the inactivation of E 2 and to the increased activity of antioxidant enzymes need to be considered as determinants for E 2 -dependent mammary tumor formation in the ACI rat model.
